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Abstract
Systemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant development
in the past 15 years. Therapy regimens consisting of combinations of cytotoxic chemotherapeutic agents
have demonstrated greater efficacy and contributed to a significant survival improvement. As the majority
of patients who undergo resection for liver-only CRLM are at risk of disease recurrence and cancer-related
death, combining resection with systemic therapy appears sensible. However, trial-based evidence is
sparse to support this concept. Peri-operative FOLFOX has demonstrated a progression-free survival
benefit in a single Phase III trial; the safety of chemotherapy and subsequent operations was acceptable
and only a few patients showed initial progression. Chemotherapy-associated liver injury (CALI), including
sinusoidal obstruction syndrome and steatohepatitis, has been observed after cytotoxic therapy, and
should have implications for chemotherapy plans prior to hepatectomy. In general, pre-operative chemo-
therapy should not extend beyond 3 months. For patients with unresectable liver-only CRLM, a response
to chemotherapy could establish resectability and should be considered an initial treatment goal. In
patients with unresectable CRLM, oxaliplatin- or irinotecan-containing combinations represent the stand-
ard options, although single-agent choices may be appropriate for individual patients. The addition of
bevacizumab carries the potential for a greater response and possibly for reduced CALI risks. In tumours
without K-ras mutations, anti-epidermal growth factor receptor (EGFR) agents are also reasonable
choices for a greater response and improved survival outcomes. It is crucial that all systemic CRLM
treatment decisions include proper definitions of treatment goals and endpoints, and are derived
based on appropriate multidisciplinary considerations for other potentially applicable local or regional
modalities.
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Systemic therapies for resectable disease
Nearly half of the patients with metastatic colorectal cancer
(mCRC) present with metastases confined to the liver.1 In this
setting, a complete surgical resection of all known disease pro-
vides the only chance of a cure and when feasible, should always be
considered as part of the integrated multidisciplinary treatment.
The aim of combining chemotherapy and surgical treatment of
colorectal liver metastases (CRLM) is to reduce cancer relapse that
occurs in approximately 70% of patients after resection, and
thereby to impart a survival benefit. Before the availability of
contemporary chemotherapeutic agents, surgical resection series
of CRLM reported overall 5-year survival rates of 30% to 40%.2,3
The rationale to improve these survival outcomes after a hepate-
ctomy with additional systemic therapy has now been explored
through post-operative and pre- or peri-operative application of
chemotherapy.
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Postoperative or adjuvant chemotherapy
Systemic 5-fluorouracil (5-FU)-based chemotherapy after resec-
tion of CRLM has been widely applied and reported, but only
been evaluated in two prospective randomized trials.4,5 As both
trials had insufficient power, a pooled analysis of these two trials
showed that post-operative 5-FU-based chemotherapy was asso-
ciated with a trend towards improved disease-free survival.6 The
benefit was not statistically significant, as the median progression-
free survival (PFS) was 27.9 months in the surgery plus chemo-
therapy versus 18.8 months in the surgery alone group [hazard
ratio (HR): 1.32; 95% confidence interval (CI): 1.0–1.8; P =
0.058];6 the median overall survival (OS) was 62 months after
chemotherapy compared with 47 months without (HR: 1.32; 95%
CI: 0.95–1.82; P = 0.095). The use of irinotecan or oxaliplatin as an
adjuvant therapy for patients after hepatic resection of CRLM has
been studied. No benefit was found over 5-FU-lecovorin (LV)
alone for an irinotecan-containing chemotherapy regimen in a
Phase III randomized controlled trial.7 There are no randomized
studies comparing oxaliplatin-containing post-operative chemo-
therapy regimens and 5-FU-LV. However, in the United States,
the combination of 5-FU, folinic acid and oxaliplatin (FOLFOX)
is a widely used regimen for post-resection treatment.8 Survival
results after adjuvant FOLFOX in single-centre series have been
superior to the pre-oxaliplatin era, with a 5-year overall survival
(OS) of around 55%.9,10 In contrast to the use of FOLFOX, there is
no established role for biological-targeted agents in the use of
post-operative treatment after CRLM resection.
Adjuvant hepatic artery infusion therapy has been evaluated in
phase II and phase III trials.11–13 Different regimens including
5-FU or floxuridine have been tested, and have primarily led to a
liver recurrence-free survival (RFS) benefit. Because of a lack of
long-term OS benefits,13 the hepatic artery infusion approach has
not been generally accepted as a standard of care.
Pre- and peri-operative chemotherapy
The potential advantages of pre-operative chemotherapy are: to
facilitate resection of a large tumour in the situation of a major
response; to assess the tumour responsiveness to the agents used;
and to induce a pathological response that has been shown to be
a strong predictor of outcome after resection of CRLM.14,15 The
EORTC 40983 intergroup phase III trial study has compared peri-
operative chemotherapy with 5-FU, leucovorin and oxaliplatin
with surgery alone in 364 patients with 1 to 4 potentially resect-
able CRLM.16 After a median follow-up of 3.9 years, the primary
endpoint of PFS at 3 years in eligible patients was increased by
8.1% in the peri-operative chemotherapy + surgery group versus
the surgery alone group (36.1% versus 28.1% respectively; P =
0.041). In summary, this study showed that peri-operative
FOLFOX4 chemotherapy contributed to a significant delay of
cancer recurrence, and was compatible with major surgical treat-
ment.16 Several general underlying characteristics of this trial are
noteworthy: first, the absolute benefit in PFS observed with the
combination of chemotherapy compared with resection alone (8
to 9%) is within the range of that observed in other positive trials
in gastrointestinal oncology. Second, although patients were sup-
posed to have resectable metastases at diagnosis, 17% of patients
in each treatment arm could not undergo resection mainly
because of more extensive disease than expected at randomiza-
tion. Inability to resect was considered as an early event for PFS.
Third, according to protocol patients in the combined treatment
arm underwent resection with a time delay of 4 months compared
with the resection-only group. This difference in lead time was
addressed by considering that all events between weeks 0 and 20
were set at week 10, which explains the early drop in the PFS
curves. Fourth, the results of EORTC 40983 and of the meta-
analysis of two trials of post-operative chemotherapy6 cannot be
compared, as the patient populations were different. Ineligible
patients, patients with unresected metastases and patients with
post-operative complications that delay or prohibit post-operative
chemotherapy remain in the analysis of EORTC study 40983, but
are excluded from trials evaluating post-operative treatment
because randomization takes place after patients have recovered
from the operation and a final pathological report is obtained.
Tumour progression of CRLM during chemotherapy has been
regarded as a potential disadvantage of pre-operative chemo-
therapy. In the EORTC Intergroup phase III study 40983, progres-
sive disease was observed in 12 out of 182 (7%) and was in the
majority as a result of the appearance of new extra-hepatic lesions;
it is likely that these new lesions would have occurred after imme-
diate resection, too, and it can be considered an advantage to
discover them before an unnecessary operation. The results of the
EORTC 40983 trial also confirm that the use of pre-operative
chemotherapy is associated with a slight but significant increase in
the risk of post-operative reversible complications.16 Of note,
these complications resulted mainly in a prolongation of the hos-
pital stay, while the mortality rate was not affected.
Some other important principles regarding pre-operative
therapy for resectable CRLM have been obtained from outcome
evaluations with lower-level evidence. The duration of pre-
operative chemotherapy has been shown to correlate with the
post-operative complication rate after CRLM resection; more
than six pre-operative treatment cycles are thus not recommended
for resectable disease.17 In addition, extensive pre-operative
chemotherapy does not improve the pathological response, but
increases the risk for post-operative liver insufficiency.18 There is
an interest in combining targeted agents with chemotherapy such
as FOLFOX in patients who are candidates for resection of CRLM.
This is currently being evaluated in randomized controlled trials,
such as in the EORTC trial 40091 evaluating the addition of
bevacizumab or panitumumab to FOLFOX (NCT01508000).
In contrast to other cancer resections, initial evidence for the
pre-operative addition of the vascular endothelial growth factor
(VEGF) antibody bevacizumab indicates that pre-operative beva-
cizumab does not increase the morbidity of a subsequent CRLM
resection.19 In addition, bevacizumab may protect against
oxaliplatin-induced liver injury.20 Interesting preliminary results
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with respect to survival outcomes after resection of patients
peri-operatively treated with bevacizumab-containing regimens
reported a promising 89% 2-year OS.21
Altogether, the use of pre-operative chemotherapy is safe pro-
vided careful monitoring of the duration of the treatment.16,19–21 In
patients with resectable CRLM, a liver resection can be proposed
after short-course chemotherapy, i.e. four to six cycles. At the
moment, no objective data exist that support the combination of
cytotoxic and biological agents for the peri-operative treatment of
patients with resectable CRLM. Ongoing and future clinical trials
are addressing this question. A formal multidisciplinary evalua-
tion for patients with resectable CRLM is recommended prior to
any therapy initiation, so that peri- versus post-operative treat-
ment plans and the exact duration of any pre-operative compo-
nent can be determined up front. Based on retrospective evidence,
pre-operative chemotherapy is generally not recommended for a
longer duration than 3 months if a resection can take place at that
time point.17,18
Consensus statement
1 For resectable CRLM, peri-operative chemotherapy with resec-
tion has shown progression-free benefits compared with resec-
tion alone. The use of an oxaliplatin-containing regimen is the
reference treatment for this approach.
2 In patients who did not receive pre-operative chemotherapy,
post-operative chemotherapy can be administered after resec-
tion. While FOLFOX or 5-FU-LV are acceptable choices, evi-
dence does not support FOLFIRI for this approach.
3 Targeted agents can be considered as part of pre-operative
therapy regimens for CRLM based on higher response rates and
the potential for protection against liver injury in spite of the
absence of level I evidence.
Systemic cytotoxic therapies for
unresectable disease
The majority of patients with colorectal cancer who develop
metastatic disease do not have resectable CRLM. However, in part
as a result of advances in systemic therapy, those patients with
unresectable CRLM are now living longer than ever before. This
section will address approaches to newly diagnosed patients with
unresectable CRLM with no prior treatments. Treatment goals
in this patient group vary widely, from establishing resectability
of liver-only CRLM through to systemic treatment over life-
prolonging but non-curative therapy to means of disease-specific
symptom-oriented palliation.
Chemotherapy remains the core of mCRC treatment. Infu-
sional fluoropyrimidine schedules have by now been widely
embraced. The results of Tournigand et al., indicating that there is
no significant difference between FOLFIRI (folinic acid, infu-
sional and bolus 5-FU and irinotecan) and FOLFOX regimens as
first-line mCRC therapy when patients are switched to the other
regimen upon progression, have been seen elsewhere, although no
true non-inferiority study has ever been conducted.22,23 However,
while there is good evidence that in second-line therapy oxalipla-
tin should be given together with 5-FU, no information suggests
that FOLFIRI after FOLFOX is superior to irinotecan alone.24
Therefore, starting with FOLFOX as first-line chemotherapy, the
choice of next regimens can be either FOLFIRI or single agent
irinotecan. However, if starting with FOLFIRI, then single agent
oxaliplatin is not a reasonable second-line regimen.24 Regardless
of the sequence, it is clear that as more chemotherapy agents have
become available and larger numbers of patients have been
exposed to all three active agents (5-FU, irinotecan and oxalipla-
tin), survival has increased, at least for those eligible for clinical
trials.25
The newer regimens, FOLFIRI and FOLFOX, have resulted in
significantly longer PFS in first-line therapy.22,23,26–28 This is par-
ticularly important in the use of oxaliplatin with its potential for
cumulative neuropathy. To study the means of ameliorating neu-
ropathy and optimizing the use of oxaliplatin, the OPTIMOX trial
randomized patients to either FOLFOX7 for six cycles followed by
the 5-FU-LV regimen without oxaliplatin, and upon progression
or after a set time to reintroduce oxaliplatin, versus FOLFOX4
until disease progression;28 relevant differences between the regi-
mens are the higher dose of oxaliplatin (130 mg/m2) and the lack
of a bolus 5-FU in FOLFOX. This trial showed no differences in
the response rate (RR), OS or PFS for the ‘OPTIMOX’ regimen
(FOLFOX 7 arm) compared with standard FOLFOX 4.28 Neuropa-
thy was less severe in the OPTIMOX arm. Many patients in the
OPTIMOX arm never had oxaliplatin re-introduced as suggested
by the study; those patients who did, appeared to do better, sug-
gesting that this strategy may have more benefits than simply
reducing neuropathy.28 Subsequently, a randomized phase II trial,
OPTIMOX 2, was conducted comparing the original OPTIMOX
regimen with a slightly lower dose of oxaliplatin (100 mg/m2) and
5-FU-LV versus no chemotherapy during the treatment-free
interval.29 In this study, the primary endpoint of duration of
disease control (13.1 versus 9.2 months; P = 0.046) and the sec-
ondary endpoint of PFS (8.6 versus 6.6 months; P = 0.0017) were
inferior when all chemotherapy was stopped. OS results suggested
that full breaks may be inferior (23.8 versus 19.5 months) but
failed to reach statistical significance (P = 0.42). Therefore, caution
should be taken in stopping all drugs before progression in first-
line therapy of mCRC. Regarding treatment breaks from
FOLFIRI, one study randomized patients to either continuous
FOLFIRI versus 2 months of treatments alternating with
2 months off chemotherapy.30 There was no difference in PFS (6.5
versus 6.2 months, P = NS) or OS (16.9 versus 17.6 months, P =
NS) between the two arms, although the frequency of disease
evaluation was less than in most mCRC trials.30 In a second-line
setting, a small randomized trial of stopping irinotecan after
6 months versus continuing irinotecan showed no survival differ-
ence, but because of randomization at initiation of second-line
irinotecan the majority of patients had progressed prior to the
6-month time point resulting in a very underpowered study.31
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Another important question revolves around the need for
aggressive therapy at the start. Two randomized trials32,33 sug-
gested that starting with 5-FU-LV (on the MRC FOCUS trial) or
with capecitabine (on the CAIRO trial) had a shorter PFS but
similar OS compared with starting with combination chemo-
therapy in first-line therapy. Importantly, survival times on the
MRC FOCUS trial were generally lower (range: 13.9–
16.7 months on 5 arms) than are obtained on most current phase
III trials in mCRC.32 While these data suggest that there is prob-
ably a patient population that might benefit from a less aggres-
sive initial approach, it is difficult to recommend starting a good
performance status patient with a regimen that will be effective
for a shorter duration of time. In stark contrast to CAIRO and
FOCUS, the Italian FOLFOXIRI (folinic acid, oxaliplatin and iri-
notecan) trial randomized patients to this 3-agent regimen versus
FOLFIRI;34 FOLFOXIRI patients had a better OS (22.6 versus
16.7 months, P = 0.032) and PFS (9.8 versus 6.9 months, P =
0.0006) compared with FOLFIRI, with a tolerable toxicity profile.
However, a second trial performed in Greece with a slightly dif-
ferent regimen of FOLFOXIRI compared with FOLFIRI did not
demonstrate any difference in OS (21.5 versus 19.5 months) or
PFS (8.4 versus 6.9 months).35
Based on their response to initial chemotherapy, some patients
with initially unresectable CRLM may be rendered candidates for
resection.As their outcomemirrors that of patients with primarily
resectable CRLM, this sub-group of patients should also be con-
sidered for operative therapy.36 These considerations are of crucial
importance to select the best first-line therapy. Indeed, a linear
correlation has been shown between RR and the surgical resection
rate underlining the importance of developing increasingly active
regimens for this purpose.37 Quality of imaging, completeness of
staging, type and duration of induction therapy are all crucial
components that influence subsequent resection options and
patient outcomes.
Consensus statement
1 For unresectable CRLM, it is crucial to establish the overall goal
of therapy prior to choosing the regimen: downsizing the
tumour for potential resection versus non-curative therapy
with prolongation of survival.
2 For downsizing of CRLM, while FOLFOX and FOLFIRI repre-
sent two chemotherapy backbones of similar efficacy, there is
a possibility that the three-drug regimen FOLFOXIRI may
provide a higher likelihood of a response.
3 For non-curative therapy of mCRC, while FOLFOX and
FOLFIRI represent two chemotherapy backbones of similar
efficacy, there may be some patients for whom a less aggressive,
initially single-agent approach is appropriate.
4 Capecitabine plus oxaliplatin represents a reasonable alterna-
tive to FOLFOX, but capecitabine plus irinotecan is not an
alternative to FOLFIRI. Single-agent capecitabine should not be
used after progression on prior 5-FU-containing regimens.
Molecular targeted therapies
The combination of 5FU-LV with oxaliplatin (FOLFOX) or iri-
notecan (FOLFIRI) have traditionally represented the two main
treatment options for mCRC. The therapeutic algorithm for
mCRC has become more complex with the introduction of tar-
geted agents.38–41 While anti-EGFR agents cetuximab and panitu-
mumab have revealed their efficacy in improving the tumour RR,
treatment with the anti-VEGF antibody bevacizumab has demon-
strated minor shrinkage activity and more consistently delayed
tumour progression.39,40,42
The first targeted agent to show efficacy in a randomized trial
for mCRC was bevacizumab, an antibody to VEGF-A. When
added to IFL (irinotecan, bolus 5-FU and leucovorin), survival
was better with bevacizumab than with the placebo (20.3 versus
15.6 months, respectively, P < 0.0001).39 Similar but non-
significant results for OS were determined for 5-FU-LV + bevaci-
zumab compared with 5-FU-LV alone in a smaller randomized
phase II trial (16.6 versus 12.9 months, respectively, P = 0.16).43
However, as IFL was no longer in widespread use, bevacizumab
has largely been given with FOLFOX or FOLFIRI. In combination
with second-line FOLFOX, bevacizumab significantly prolonged
PFS (7.3 versus 4.7 months, P < 0.0001) and OS (12.9 versus 10.8
months, P = 0.0011) compared with FOLFOX alone in E3200;44
however, the HR of 0.83 (95% CI: 0.72–0.95, P = 0.0023) was not
as good when bevacizumab was added to first-line FOLFOX in the
N016966 trial.38 FOLFIRI was never tested against FOLFIRI +
bevacizumab in a randomized trial, but the OS for FOLFIRI +
bevacizumab of 28 months in the BICC-C trial was among the
longest seen in a randomized trial in patients with mCRC.27,45
Observational cohort studies have twice demonstrated a longer
survival for patients treated with bevacizumab beyond progres-
sion (BBP) after disease progression on bevacizumab-containing
first-line therapy, but treatment choices and decision making were
not randomized or controlled.46,47 Therefore, they primarily serve
as hypothesis-generating data sets for an ongoing trial that com-
pares BBP + chemotherapy to chemotherapy alone in second-
line treatment of mCRC. In recently released information,
bevacizumab prolonged the survival of patients treated beyond
progression.48
Amongmultiple inhibitors of VEGF signaling,49 two agents that
target VEGF have recently demonstrated evidence of activity in
patients with mCRC. Aflibercept (VEGF trap), a unique VEGFR
fusion agent that is likely to bind more forms of VEGF than
bevacizumab, was studied in a randomized trial of second-line
aflibercept + FOLFIRI versus FOLFIRI alone, with the aflibercept
arm yielding significantly longer PFS and OS.50 The median OS
was 13.5 months for aflibercept and 12.06 months for placebo
(HR = 0.817; 95.34%CI, 0.713–0.937; P = 0.0032).51 This held true
for all subsets of patients on the study including those who had
previously received bevacizumab. How this agent is integrated
into the therapy of mCRC may depend in part on the presented
results of the randomized trial evaluating the question of BBP.48
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The second agent, regorafenib, is a tyrosine kinase inhibitor (TKI)
of the VEGF receptors in addition to other receptor tyrosine
kinases.52 As last line therapy, this agent was tested against best
supportive care in a randomized trial.52 A total of 760 patients
were randomized in a 2:1 fashion to regorafenib or placebo.
Regorafenib succeeded in achieving its endpoints, including the
primary endpoint of OS, extending the median survival by
1.4 months from 5 to 6.4 months with a HR of 0.77 (P = 0.0052).52
The PFS was also improved with a HR of 0.47 (P < 0.00001).52
Toxicity in form of hand–foot syndrome, fatigue, diarrhoea,
hypertension etc. led to discontinuation of regorafenib in 8.2%
compared with 1.2% in patients receiving the placebo.52 Other
VEGF inhibitors are still being evaluated in patients with mCRC
and may also prove beneficial.
The other known target for biological agents in patients with
mCRC is EGFR. Blocking EGFR with antibodies, such as panitu-
mumab or cetuximab, has resulted in a clinical benefit for patients
with mCRC. Cetuximab as last-line therapy for unselected
patients resulted in an improved OS (6.1 versus 4.6 months,
respectively, P < 0.001) and PFS compared with best supportive
care in a randomized trial with no cross-over allowed.53 In a ran-
domized trial of panitumumab versus best supportive care allow-
ing cross-over, survival was not significantly different for the two
arms, but the PFS (1.9 versus 1.7 months,P < 0.001) was improved
for panitumumab-treated patients.54 Later, as K-ras was evaluated
as a biomarker of efficacy, both trials showed more clinically sig-
nificant benefits for cetuximab and panitumumab.55,56 Prior to
these two trials, the BOND trial had shown that cetuximab +
irinotecan was more effective in terms of PFS (4.1 month versus
1.5 months, P < 0.001) than cetuximab alone without improved
survival (8.6 versus 6.9 months, P = 0.48), in spite of prior
treatment with irinotecan.57 Therefore, it was logical to evaluate
panitumumab and cetuximab in earlier lines of therapy in com-
bination with common chemotherapy regimens.49 Both agents
have demonstrated improved response rates and PFS in earlier
lines of therapy when added to chemotherapy compared with
chemotherapy alone, but with multiple lines of therapy now avail-
able, it is increasingly difficult to see differences in OS on first-line
and even second-line trials. Of note, K-ras mutations have clearly
been a biomarker of efficacy in almost all trials with EGFR inhibi-
tors whether given alone or in combination with chemotherapy.49
Based on this insight, it appears reasonable to propose a
simplified algorithm consisting of cetuximab, panitumumab or
bevacizumab-based treatment in patients with K-ras wild-type
and bevacizumab-based treatment in patients with K-ras mutant
tumours.58 There is no current consensus among oncologists to
favour either targeted therapy for patients with unresectable
CRLM andK-ras wild-type tumours. First, to date, no randomized
studies have provided a head-to-head comparison between these
two treatments, and the results are awaited from the CALGB-
C80405 (NCT00265850, http://clinicaltrials.gov/ct2/show/NCT
00265850) and FIRE-3 (NCT00433927, http://clinicaltrials.gov/
ct2/show/NCT00433927) trials. Moreover, one should be con-
cerned about a traditional ‘tumour response’ as the unique
objective of treatment in this setting. Even if it seems that cetuxi-
mab offers better chances of radiological tumour down-sizing
than bevacizumab, recent studies have provocatively sustained the
efficacy for the anti-VEGF strategy in inducing a high degree of
pathological responses.15 The real importance of this surrogate
end-point is not well established, but it strongly correlates with OS
after resection in patients with CRLM.15 It is important that radio-
logical or pathological responses as well as secondary resection
rates are only surrogate endpoints and in this setting, as the
primary objective is still life-prolonging, or potentially curative in
those patients who are rendered resectable.36,59
In the future, in addition to clinical considerations, molecular
markers may provide critical information for selecting patients
who might benefit preferentially from one of these drugs. Indeed,
the tumour’s pathology and patient’s metabolism is driven by
genetic make-up, influencing the individual response as well as
the agent’s toxicity. The selection of therapy should be based on
the best achievable, individualized balance of toxicity, efficacy
and costs. In contrast to the ‘good clinical practice’ of the past, as
a result of the introduction of new targeted drugs a slow but
dramatic revolution is being experienced. K-ras mutations in the
treatment of patients with mCRC are a clear example of how a
molecular marker has completely changed the way clinicians
approach everyday clinical decision-making.60–62 The challenge of
a treatments’ optimization through specific biomarkers gain
special value for a potentially curable disease such as CRLM.
Unfortunately, progress in utilizing biomarker-driven treatment
decisions has been slow for at least two reasons. First, the high
degree of complexity of the biological systems makes the discov-
ery of determinant biomarkers a demanding endeavour per se.
On the other hand, researchers face all the difficulties of prospec-
tive verification and clinical validation of the most promising
factors. Nevertheless, molecular-targeted therapy has entered the
arena of mCRC combination therapy, and further significant
advances in molecular-targeted systemic therapy are expected in
the future.
Consensus statement
1 Anti-VEGF- and anti-EGFR-targeted antibodies have increased
the efficacy of chemotherapy in first-, second- and third-line
treatment.
2 Bevacizumab is an appropriate biological agent to add to either
first- and/or second-line chemotherapy backbones.
3 The EGFR inhibitors panitumumab or cetuximab are appro-
priate for first-, second- or third-line use in combination with
chemotherapy, or as single third-line agents, but only in
patients with wild-type K-ras.
4 Predictive markers such as K-ras should be used when
possible to increase the efficacy of combination molecular-
chemotherapeutic regimens.
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5 Patients with metastatic disease who have a response to chemo-
therapy in combination with targeted antibodies may still
benefit from subsequent curative-intent resection.
Hepatotoxicity of chemotherapy
A potential drawback to the evolving options for pre-operative
CRLM cytotoxic chemotherapy-based treatment rests in
chemotherapy-associated liver injury (CALI). Clinical conse-
quences of CALI have recently been characterized in this setting
and are the subject of active investigation. The three recognized
types of CALI include steatosis, steatohepatitis, and sinusoidal
obstruction syndrome, and their prevalence, aetiology related to
chemotherapeutic regimen and clinical implications are well
established today.
Steatosis corresponds to accumulation of lipids in hepatocytes
and has been reported by some in 30% of patients treated with
5-FU.63,64 Steatosis may have multiple causes. Its incidence is
common and ranges from 15% of the general population in Italy
to 31% in the USA, affecting primarily individuals with risk con-
ditions such as obesity, diabetes or alcohol consumption.65 Studies
associating steatosis and 5-FU are mainly based on radiological
evaluation. However, ultrasound sensitivity for diagnosis of stea-
tosis is only 60–94% and specificity is 66–95%, whereas CT-scan
sensitivity is 82% and specificity is 100%.65 Of note, imaging
cannot distinguish steatosis from steatohepatitis.66 The few studies
that include histological evaluation have not included a liver
biopsy before pre-operative chemotherapy.
The steatohepatitis (SH) diagnosis is based on a histological
triad: steatosis, hepatocellular ballooning and polymorphonuclear
neutrophil inflammation. Its link to the use of chemotherapy is
not uniformly established. Chemotherapy associated SH (CASH)
has mainly been reported by North-American authors67–69 and
may be partly explained by the difference in average body mass
index (BMI) in the general US population. CASH has been
described after cytotoxic therapy, most often after irinotecan
treatment, particularly in the at risk population of non-alcoholic
liver disease, with a BMI of >25 kg/m2. Macroscopically, it results
in a ‘yellow liver’.
Sinusoidal obstruction syndrome (SOS, previously named
veno-occlusive disease or VOD) has been associated with the use
of oxaliplatin.17,68–76 Macroscopically, the affected liver typically
has a blue-red marbled appearance, commonly called ‘blue liver’.
SOS is the consequence of an initial toxicity to sinusoidal
endothelial cells.77 Histologically, it is characterized by centrilobu-
lar sinusoidal dilatation, often associated with erythrocyte
extravazation into the persinusoidal space (haemorrhage), com-
patible with a rupture of the sinusoidal wall. It is occasionally
associated with perisinusoidal fibrosis and centrilobular vein
obstruction, in addition to peliosis or the development of nodular
regenerative hyperplasia (NRH).71
From a clinician’s perspective, the implications of CALI have
been elucidated within the pre-operative, operative or early post-
operative period. Post-operative morbidity correlates with the
number of cycles of pre-operative chemotherapy.17 CALI can spe-
cifically prolong the operative procedure and the subsequent hos-
pital stay, decrease the accuracy of metastasis detection at the time
of pre-operative imaging assessment, increase the risks of peri-
operative haemorrhage, post-operative infections, liver failure
after a major hepatectomy owing to poor liver function reserve,
portal hypertension or ascites and be responsible for a persistent
thrombocytopenia.18,78–80 Rare cases of death as a result of CALI
have been reported.81
Although a reliable diagnosis of CALI is essential to allow for a
proper selection of patients for liver operations, the current
absence of specific diagnostic tools makes pre-operative recogni-
tion especially of SOS challenging. SOS risk factors may include
abnormal pre-operative gamma-GTP or APRI value (ratio index
of aspartate aminotransferase to platelet count),82 age, female gen-
der,75 the indocyanin green retention rate, the number of cycles of
chemotherapy,17 or a short interval between the end of chemo-
therapy and the liver resection.83 Computed tomography is not
directly diagnostic83,84 but can play a role in supporting the diag-
nosis through demonstrating the presence of splenomegaly85 and
ascites.
As many patients still experience recurrence of CRLM after
initial multidisciplinary treatment, subsequent cytotoxic and local
therapies frequently need to be decided upon. An open question
therefore is whether CALI, notably SOS and NRH, is reversible
once the cause has stopped, and if so, in which time frame. For the
short term, the histological persistence of SOS and NRH is
observed in the setting of two-stage hepatectomies, suggesting that
there is no advantage in delaying anoperation that is otherwisewell
timed in terms of tumour response to chemotherapy. Increased
post-operative morbidity associated with an early hepatectomy
performed within 4 weeks of pre-operative chemotherapy com-
paredwith later operations therefore does not appear to be linkable
to the histological manifestation of CALI.86 For the long term, the
question of persistence is less certain: analogy with settings of toxic
oil syndrome in which NRH and portal hypertension was noted
2.5 years after consuming the oil, and of azathioprine and 6TG
treatment suggest that changes are not always reversible; persistent
SOS,NRHandevenfibrosismayoccur severalmonths after the end
of chemotherapy.87 While a SOS-associated splenomegaly can
decrease over 1–3 years,79,85 the incidence of chronic liver disease is
not yet well evaluated, particularly for patients who receive multi-
ple cycles of adjuvant or maintenance chemotherapy.
A better comprehension of the molecular events underlying
chemotherapy-associated hepatic injury might also be a source of
help in patient management. Global gene analysis has shown acti-
vation of several pathways in human liver with oxaliplatin-related
SOS, namely acute phase response, coagulation, fibrosis/hepatic
stellate cell activation, oxidative stress, hypoxia and angiogenesis.88
This provides new insights into mechanisms underlying CALI in
humans and potential targets relating to its diagnosis, prevention
and treatment. Activation of VEGF and coagulation pathways
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could explain, at a molecular level, the clinical observations that
bevacizumab20,71,76,89 and aspirin69 have a preventive effect in SOS.
In case of aspirin, a significantly decreased frequency of CALI had
been observed in a multivariate analysis of 146 patients undergo-
ing a liver resection within 3 months of chemotherapy (HR: 0.07,
95% CI: 0.01–0.37; P = 0.002).69
Consensus statement
1 Cytotoxic chemotherapy may have drawbacks with potential
clinical consequences, especially when given before a major
hepatic resection. Risks for significant chemotherapy-
associated liver injury need to be balanced against benefits in
patients for whom resection of CRLM is planned.
2 Clinically relevant CALI has been linked to specific agents: stea-
tohepatitis is associated with irinotecan, whereas SOS, fibrosis
and NRH are associated with oxaliplatin
3 Bevacizumab and aspirin have demonstrated some preventive
effect on SOS severity.
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